# PRODUCT INFORMATION



## Cefuroxime-d<sub>3</sub> Item No. 31163

CAS Registry No.: 1803240-98-3

Formal Name: (6R,7R)-3-((carbamoyloxy)methyl)-

7-((Z)-2-(furan-2-yl)-2-((methoxy-d<sub>2</sub>) imino)acetamido)-8-oxo-5-thia-1azabicyclo[4.2.0]oct-2-ene-2-carboxylic

MF:  $C_{16}H_{13}D_3N_4O_8S$ 

FW: 427.4


**Chemical Purity:** ≥95% (Cefuroxime)

Deuterium

 $\geq$ 99% deuterated forms (d<sub>1</sub>-d<sub>3</sub>);  $\leq$ 1% d<sub>0</sub> Incorporation:

Supplied as: A solid -20°C Storage: ≥4 years Stability:

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



### **Laboratory Procedures**

Cefuroxime-d<sub>3</sub> is intended for use as an internal standard for the quantification of cefuroxime (Item No. 23627) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Cefuroxime-d<sub>3</sub> is supplied as a solid. A stock solution may be made by dissolving the cefuroxime-d<sub>3</sub> in the solvent of choice, which should be purged with an inert gas. Cefuroxime-d<sub>3</sub> is slightly soluble in DMŠO and in methanol (warmed).

#### Description

Cefuroxime is a cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria including S. pyogenes, S. pneumoniae, S. viridans, E. coli, P. mirabilis, H. influenzae, and N. gonorrhoeae (mean MICs = 0.005-8.2 μg/ml). Like other cephalosporins, cefuroxime inhibits peptidoglycan crosslinking and bacterial cell wall synthesis.<sup>2</sup> It is resistant to hydrolysis by bacterial β-lactamases, increasing its efficacy against β-lactamase-producing Gram-negative bacteria.<sup>3</sup> Cefuroxime is protective against Gram-positive and Gram-negative infections in vivo with mean ED<sub>50</sub> values ranging from 2 to 35 and 1 to 55 mg/kg, in mice and rats, respectively.<sup>4</sup> Formulations containing cefuroxime have been used to treat urinary tract infections.

#### References

- 1. O'Callaghan, C.H., Sykes, R.B., Griffiths, A., et al. Antimicrob. Agents Chemother. 9(3), 511-519 (1976).
- 2. Curtis, N.A.C., Hughes, J.M., and Ross, G.W. Antimicrob. Agents Chemother. 9(2), 208-213 (1976).
- 3. Richmond, M.H. and Wotton, S. Antimicrob. Agents Chemother. 10(2), 219-222 (1976).
- 4. Ryan, D.M., O'Callaghan, C.H., and Muggleton, P.W. Antimicrob. Agents Chemother. 9(3), 520-525 (1976).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

## **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM